Verastem

• NCT07318324

  Collaborator, Phase 1, Recruiting, 31 people, 6 Jan 2026

• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  Phase 1/2, Recruiting, 616 people, 13 Jun 2025

• NCT06394804

  Collaborator, Phase 2, Recruiting, 20 people, 1 May 2024

• A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  Phase 3, Recruiting, 270 people, 10 Oct 2023

• NCT05608252

  Collaborator, Phase 1/2, Recruiting, 63 people, 8 Nov 2022

• NCT03287271

  Collaborator, Phase 1/2, Terminated, 8 people, 19 Sept 2017

• NCT02407509

  Collaborator, Phase 1, Completed, 104 people, 3 Apr 2015

Sources: clinicaltrials.gov